Bridge Biotherapeutics to Present Key Developments at JPM 2025
Bridge Biotherapeutics, a clinical-stage biotech company focusing on therapeutic areas with high unmet needs, has officially been slated to present at the 43rd annual J.P. Morgan Healthcare Conference.
Johnson & Johnson Expands Atopic Dermatitis Portfolio
Johnson & Johnson has entered an exclusive licensing agreement with Kaken Pharmaceutical for Kaken's STAT6 program, including lead candidate KP-723, an oral treatment which targets autoimmune and allergic diseases such as atopic dermatitis.
WuXi AppTec to Sell WuXi Advanced Therapies to Altaris, LLC
WuXi AppTec announced the sale of WuXi Advanced Therapies (ATU) operations to healthcare investment firm Altaris, LLC.
SiteOne Therapeutics Secures $100M to Advance Non-Opioid Pain Drug Research
SiteOne Therapeutics lands $100M in funding to develop non-opioid pain medications. Backed by Novo Holdings, the biotech firm aims to demonstrate the effectiveness of its ion channel-focused treatments amidst a challenging market landscape.
Pfizer Projects $1 Billion Revenue Impact from IRA Changes and Foresees No Major M&A in 2025
Pfizer anticipates a $1 billion revenue reduction in 2025 due to Medicare Part D redesign while maintaining revenue forecasts. The company plans no major acquisitions, focusing instead on cost savings and operational growth.
Novo Nordisk Announces Significant Insulin Price Cuts for 2026
Novo Nordisk plans to reduce U.S. insulin prices significantly by 2026, aligning with Medicare mandates. The cuts follow industry trends and government pressure to lower diabetes treatment costs.
The Decline of Retail Pharmacies: A Decade of Closures and Disparities
Discover the findings of a Health Affairs study revealing the closure of one in three U.S. pharmacies since 2010, with independent pharmacies and marginalized communities hit hardest. Learn about the role of pharmacy benefit managers in this trend and its impact on healthcare disparities.
Sanofi Unveils $590M Modular Vaccine and Biologics Plant in Singapore
Sanofi has opened a $590 million modular manufacturing facility in Singapore's Tuas Biomedical Park, designed to swiftly adapt production lines for vaccines and biologics. This innovative plant, operational by 2026, aims to bolster pandemic preparedness and strengthen Singapore's biopharma manufacturing presence.
High Out-of-Pocket Costs Leave Nearly a Quarter of Americans Underinsured, Survey Reveals
A recent Commonwealth Fund survey highlights that 23% of working-age Americans are underinsured, facing high out-of-pocket costs that hinder access to necessary healthcare. The report also notes significant coverage gaps, with many delaying care due to cost barriers.
Biden Administration Proposes Expanding Medicare & Medicaid Coverage for Weight Loss Drugs
The Biden administration proposes a rule to allow Medicare and Medicaid to cover anti-obesity drugs like Wegovy and Zepbound, potentially providing access to millions but posing a $40 billion cost over a decade.
BeiGene Settles Patent Dispute with MSN to Protect Cancer Drug Until 2037
BeiGene secures Brukinsa's market exclusivity until 2037 through a patent settlement with MSN Pharmaceuticals, resolving litigation and safeguarding its blockbuster cancer drug. The agreement allows MSN to launch a generic version in the U.S. in 2037, barring any accelerations or extensions. Concurrently, BeiGene is rebranding to BeOne Medicines as it expands its global cancer drug offerings.
UPDATE: Eli Lilly Joins J&J in Challenging Federal 340B Drug Discount Program in Court
Eli Lilly and Johnson & Johnson have filed lawsuits against the U.S. government over the administration of the 340B drug discount program, seeking to implement rebate systems for hospitals instead of providing upfront drug discounts. The legal actions highlight ongoing tensions between pharmaceutical companies and healthcare providers over program costs and compliance.
Johnson & Johnson Challenges Federal Government Over 340B Rebate Plan
Johnson & Johnson has filed a lawsuit against the Biden administration, seeking to implement a rebate model for the 340B drug discount program. The pharmaceutical giant aims to replace upfront discounts with after-the-fact rebates, a move met with opposition from hospitals and federal regulators.
Senate Scrutiny on Pfizer and Lilly’s Telehealth Platforms Over Potential Anti-Kickback Violations
Pfizer and Eli Lilly face Senate inquiries over their telehealth prescription platforms amid concerns of potential violations of anti-kickback rules and inappropriate prescribing practices. Lawmakers are demanding clarity on these direct-to-patient programs.
AbbVie Loses $40 Billion in Market Value as Schizophrenia Drug Trials Disappoint
AbbVie experiences a $40 billion market value drop after its schizophrenia drug, emraclidine, fails in Phase 2 trials. Discover the implications of this failure and what it means for AbbVie’s future in neuroscience.
ModEx: Revolutionizing Cancer Drug Pricing and Access Through Open-Source Health Economic Models
Discover how ModEx is transforming cancer drug pricing and accessibility by providing a decentralized platform for open-source health economic models. Learn about the innovative approach to model sharing, including royalty incentives for developers and enhanced validation for users, aimed at ensuring cost-effective healthcare solutions.
Axonis Secures $115M to Advance Precision Neurological Therapies
Axonis Therapeutics, a burgeoning biotechnology company, has successfully secured $115 million in funding to advance its [...]
Septerna’s $288M Upsized IPO Fuels Ambitious GPCR Drug Development
Septerna, a clinical-stage biotech company specializing in GPCR-targeted drugs, successfully raised $288 million through an upsized [...]
Terray Therapeutics Raises $120M to Propel AI-Driven Small Molecule Discovery
Terray Therapeutics has raised $120 million in an oversubscribed Series B funding round, with hopes to [...]
UnitedHealth Challenges CMS Over Medicare Advantage Star Ratings
UnitedHealth is suing the Centers for Medicare & Medicaid Services (CMS) over reduced star ratings for [...]
Aktis Oncology Secures $175M to Advance Innovative Radiopharmaceuticals for Solid Tumors
Aktis Oncology announced Monday morning that they have raised $175 million in an oversubscribed Series B [...]
Novartis and Generate:Biomedicines Forge $1B+ AI-Driven Partnership for Protein Therapeutics Development
Novartis has entered a collaboration with Generate:Biomedicines, a Flagship-founded biotech, in a deal potentially exceeding $1 [...]
Biotech Sector Hopes for Boost Following Federal Reserve’s Interest Rate Cut
The biotechnology sector is poised for potential growth following the Federal Reserve's decision to lower interest [...]
23andMe Board Exodus: Directors Resign Amid CEO’s Privatization Push
The independent board directors of 23andMe have resigned due to a disagreement with CEO Anne Wojcicki [...]
OrsoBio Secures $67M to Advance Combination Obesity Therapies with Focus on Mitochondrial Protonophores
California-based biotech startup OrsoBio has raised $67 million in a Series B funding round to advance [...]
